News
Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.
The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...
BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback